Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

$515.4M

Market Cap • 5/9/2025

2020

(5 years)

Founded

2020

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of DE

Tubingen

Headquarters • BW